BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30910862)

  • 1. Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.
    Do P; Beckwith KA; Cheney C; Tran M; Beaver L; Griffin BG; Mo X; Liu Y; Lapalombella R; Hertlein E; Muthusamy N; Byrd JC
    J Immunol; 2019 May; 202(9):2806-2816. PubMed ID: 30910862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody.
    Ciszak L; Frydecka I; Wolowiec D; Szteblich A; Kosmaczewska A
    Tumour Biol; 2016 Mar; 37(3):4143-57. PubMed ID: 26490985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
    Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
    Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
    Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
    J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.
    Bagnara D; Kaufman MS; Calissano C; Marsilio S; Patten PE; Simone R; Chum P; Yan XJ; Allen SL; Kolitz JE; Baskar S; Rader C; Mellstedt H; Rabbani H; Lee A; Gregersen PK; Rai KR; Chiorazzi N
    Blood; 2011 May; 117(20):5463-72. PubMed ID: 21385850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
    Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
    J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.
    Decker T; Schneller F; Kronschnabl M; Dechow T; Lipford GB; Wagner H; Peschel C
    Exp Hematol; 2000 May; 28(5):558-68. PubMed ID: 10812246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody Ki-67 identifies B and T cells in cycle in chronic lymphocytic leukemia: correlation with disease activity.
    Cordone I; Matutes E; Catovsky D
    Leukemia; 1992 Sep; 6(9):902-6. PubMed ID: 1387694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.
    Poggi A; Venturino C; Catellani S; Clavio M; Miglino M; Gobbi M; Steinle A; Ghia P; Stella S; Caligaris-Cappio F; Zocchi MR
    Cancer Res; 2004 Dec; 64(24):9172-9. PubMed ID: 15604289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
    Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
    J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.
    Gassner FJ; Zaborsky N; Catakovic K; Rebhandl S; Huemer M; Egle A; Hartmann TN; Greil R; Geisberger R
    Br J Haematol; 2015 Aug; 170(4):515-22. PubMed ID: 25940792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion.
    Asslaber D; Qi Y; Maeding N; Steiner M; Denk U; Höpner JP; Hartmann TN; Zaborsky N; Greil R; Egle A
    Blood; 2019 Nov; 134(20):1717-1729. PubMed ID: 31537531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
    Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
    Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile.
    Kiaii S; Kokhaei P; Mozaffari F; Rossmann E; Pak F; Moshfegh A; Palma M; Hansson L; Mashayekhi K; Hojjat-Farsangi M; Österborg A; Choudhury A; Mellstedt H
    Cancer Immunol Immunother; 2013 Jan; 62(1):51-63. PubMed ID: 22736254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway.
    Bozec A; Zaiss MM; Kagwiria R; Voll R; Rauh M; Chen Z; Mueller-Schmucker S; Kroczek RA; Heinzerling L; Moser M; Mellor AL; David JP; Schett G
    Sci Transl Med; 2014 May; 6(235):235ra60. PubMed ID: 24807557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice.
    Loser K; Scherer A; Krummen MB; Varga G; Higuchi T; Schwarz T; Sharpe AH; Grabbe S; Bluestone JA; Beissert S
    J Immunol; 2005 May; 174(9):5298-305. PubMed ID: 15843526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities.
    Reyes E; Prieto A; Carrion F; Garcia-Suarez J; Esquivel F; Alvarez-Mon M
    Am J Hematol; 1997 Aug; 55(4):175-82. PubMed ID: 9257876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
    Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
    Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.
    Li Y; Shi Y; McCaw L; Li YJ; Zhu F; Gorczynski R; Duncan GS; Yang B; Ben-David Y; Spaner DE
    Blood; 2015 Aug; 126(6):766-78. PubMed ID: 26041742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.
    Hock BD; MacPherson SA; McKenzie JL
    PLoS One; 2017; 12(3):e0172858. PubMed ID: 28257435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.